Adaptive Biotechnologies

Traded on the St. Petersburg Stock Exchange
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine the diagnosis and treatment of disease.
Adaptive Biotechnologies stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Adaptive Biotechnologies balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Adaptive Biotechnologies cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Adaptive Biotechnologies multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Adaptive Biotechnologies profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Adaptive Biotechnologies assets
Adaptive Biotechnologies cash flows

Adaptive Biotechnologies shares

TickerNameTypeNominal valueISINPrice
ADPT:USAdaptive BiotechnologiesCommon share-US00650F1093$2.4
Adaptive Biotechnologies news
05.05.2022
Adaptive Biotechnologies' GAAP loss for 3 months of 2022 was $62.796 million, up 54.5% from $40.642 million in the previous year. Revenue increased 0.5% to $38.62 million from $38.442 million a year earlier.
Source: {source} pictogram investors.adaptivebiotech.com
Pictogram next
16.02.2022
Adaptive Biotechnologies' GAAP loss for 2021 was $207.298 million, up 41.8% from $146.227 million in the previous year. Revenue increased 56.9% to $154.344 million from $98.382 million a year earlier.
Source: {source} pictogram investors.adaptivebiotech.com
Pictogram next
05.11.2021
Adaptive Biotechnologies' GAAP loss for 9M 2021 was $145.941 million, up 43.6% from $101.657 million in the prior year. Revenue increased 70.7% to $116.414 million from $68.197 million a year earlier.
Source: {source} pictogram investors.adaptivebiotech.com
Pictogram next
05.08.2021
Adaptive Biotechnologies reported a GAAP loss of $89.943 million for 6 months of 2021, up 38.5% from $64.938 million in the previous year. Revenue increased 83.7% to $76.947 million from $41.898 million a year earlier.
Source: {source} pictogram investors.adaptivebiotech.com
Pictogram next
All Adaptive Biotechnologies news
General information
Company nameAdaptive Biotechnologies
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address1551 EASTLAKE AVENUE EAST SUITE 200 SEATTLE WA 98102 206-659-0067
Mailing address1551 EASTLAKE AVENUE EAST SUITE 200 SEATTLE WA 98102
Websitewww.adaptivebiotech.com
Information disclosurewww.sec.gov